Tag Archive for: CytoDyn

CytoDyn has spent the past two years under siege – from the FDA, disgruntled investors and by association, the U.S. Department of Justice. Now, the company’s leadership hopes to chart a new future in non-alcoholic fatty liver disease.

The federal indictment alleged the two executives engaged in “false and misleading representations and material omissions” regarding the development of experimental monoclonal antibody leronlimab.